Inhibikase Therapeutics, Inc. Common Stock
$1.700
USD
Last updated on --.
24h volume537.46K
24h highest1.7400 USD
24h lowest1.6950 USD
24h Price movement+0.00%
IKT recent prices
24 Hours
+0.00%$0.00
30 days
-8.99%-$0.169
60 days
+8.29%+$0.131
90 days
-16.54%-$0.339
Key data
Previous close1.7000 USD
Market cap221.81M USD
Volume537.46K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-0.39000 USD
Net income (FY)-50.96M USD
Revenue (FY)--
Last report date12 May 2026
About Inhibikase Therapeutics, Inc. Common Stock
HeadquartersWILMINGTON
Employees (FY)35.00
Net income per employee (FY)-1.46M USD
Listed onNasdaq
IKT conversion tables
 |  |
|---|---|
| 0.5 IKT | 0.85 USD |
| 1 IKT | 1.700 USD |
| 5 IKT | 8.500 USD |
| 10 IKT | 17 USD |
| |
|---|---|
| 0.5 USD | 0.29412 IKT |
| 1 USD | 0.58824 IKT |
| 5 USD | 2.941 IKT |
| 10 USD | 5.882 IKT |
More to explore
Trending stock
Trending stock PERP
Trending stock token
FAQ
IKT is trading at $1.700, +0.00% over the last 24 hours. Track live moves on the price chart at the top of this page.
The IKT stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. IKT is currently trading at $1.700, +0.00% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on IKT price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. IKT's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from IKT; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against IKT's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Inhibikase Therapeutics, Inc. Common Stock's market cap is currently 221.81M USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume537.46K
24h highest1.7400 USD
24h lowest1.6950 USD
24h Price movement+0.00%
Start trade with IKT Perpetual
Sign up to trade